← Back to Search

Antioxidant

MBM-02 for Prostate Cancer

Phase 2

Waitlist Available

Research Sponsored by Matrix Biomed, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to week 20

Awards & highlights

Study Summary

This trial is testing a new drug to see if it's effective in treating prostate cancer.

Eligible Conditions

Prostate Cancer Recurrence
Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to week 20

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to week 20

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 20 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Reduction in Serum PSA

Secondary outcome measures

PSA progression

Percent Change in PSA

Trial Design

6Treatment groups

Experimental Treatment

Group I: Cohort5Experimental Treatment1 Intervention

Cohort 5 patients will administered 600 mg/day of MBM-02 for 20 weeks.

Group II: Cohort 6Experimental Treatment1 Intervention

Cohort 6 patients will administered 600 mg/day of MBM-02 for 20 weeks.

Group III: Cohort 4Experimental Treatment1 Intervention

Cohort 4 patients will administered 600 mg/day of MBM-02 for 20 weeks.

Group IV: Cohort 3Experimental Treatment1 Intervention

Cohort 3 patients will administered 1200 mg/day of MBM-02 for 20 weeks.

Group V: Cohort 2Experimental Treatment1 Intervention

Cohort 2 patients will administered 1000 mg/day of MBM-02 for 20 weeks.

Group VI: Cohort 1Experimental Treatment1 Intervention

Cohort 1 patients will administered 600 mg/day of MBM-02 for 20 weeks.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Matrix Biomed, Inc.Lead Sponsor

5 Previous Clinical Trials

195 Total Patients Enrolled

1 Trials studying Prostate Cancer

Prostate Oncology SpecialistsUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial innovative in its approach to treatment?

"Research on MBM-02 has been ongoing since 2019, when Matrix Biomed Inc. conducted their pioneering study of 120 subjects. Subsequently granted Phase 2 drug approval, this medication is now being studied in 3 separate trials at 9 different locations across the globe."

Answered by AI

Is enrollment for this research study currently available?

"Clinicaltrials.gov indicates that this particular clinical trial, which was first published on May 30th 2021 and last updated on May 3rd 2021, is not presently recruiting subjects. However, there are 2241 other trials actively in search of participants at the moment."

Answered by AI

Has the MBM-02 been officially sanctioned by the Food and Drug Administration?

"The safety of MBM-02 is rated as a 2 on our scale at Power, due to the fact that it has only undergone Phase 2 trials and so there are limited data points attesting to its efficacy."

Answered by AI

What experimental evidence has been collected regarding the effects of MBM-02?

"Currently, there are 3 ongoing investigations regarding MBM-02 with none of them being in the third phase. These trials for the medicine have 11 different locations around the world, and most notably one is located in Bronx, New york."

Answered by AI

How many participants are there for this clinical experiment?

"At present, this particular research study is no longer taking on new patients. It was initially posted in 30 May 2021 and the latest update came out during 3 May 2021. There are presently 2238 clinical trials for prostate cancer actively recruiting participants as well as three studies involving MBM-02 that can accept applicants."

Answered by AI

Recent research and studies

Molecular Cancer TherapeuticsJournal

SOD Mimetics: A Novel Class of Androgen Receptor Inhibitors That Suppresses Castration-resistant Growth of Prostate Cancer

Thomas, Rusha, and Nima Sharifi. 2012. “SOD Mimetics: A Novel Class of Androgen Receptor Inhibitors That Suppresses Castration-resistant Growth of Prostate Cancer”. Molecular Cancer Therapeutics. American Association for Cancer Research (AACR). doi:10.1158/1535-7163.mct-11-0540.

clinicaltrials.govStudy

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

2021. "MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04876755.

All > Recurrent Prostate Cancer